Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison

BACKGROUND: Everolimus and sunitinib have been approved for the treatment advanced pancreatic neuroendocrine tumors, but have not been compared to each other in a randomized trial and have not demonstrated prolonged overall survival compared to placebo. This study aimed to indirectly compare overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Signorovitch, James, Swallow, Elyse, Kantor, Evan, Wang, Xufang, Klimovsky, Judith, Haas, Tomas, Devine, Beth, Metrakos, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175512/
https://www.ncbi.nlm.nih.gov/pubmed/24314093
http://dx.doi.org/10.1186/2162-3619-2-32

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175512/
https://www.ncbi.nlm.nih.gov/pubmed/24314093
http://dx.doi.org/10.1186/2162-3619-2-32

Ejemplares similares